{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.5","upperLimit":"100.0","value":"100.00"},{"groupId":"OG001","lowerLimit":"19.4","upperLimit":"99.4","value":"75.00"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"26.5","value":"0.0"},{"groupId":"OG003","lowerLimit":"5.3","upperLimit":"85.3","value":"40.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"The DCR is defined as the percentage of patients with complete response (CR), partial response (PR) or stable disease (SD) at 16 weeks from the start of ceritinib treatment. The assessment criteria are: Solid Tumors (RECIST 1.1., Response Evaluation Criteria in Solid Tumors); GBM (RECIST 1.1 and RANO, Response Evaluation in Neuro-Oncology); Hematologic tumors (Cheson).","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with a diagnosis of ALCL histologically or cytologically confirmed to be ALK-positive","id":"OG000","title":"Anaplastic Large Cell Lymphoma (ALCL)"},{"description":"Patients diagnosed with IMT with a confirmed translocation involving the ALK gene","id":"OG001","title":"Inflammatory Myofibroblastic Tumor (IMT)"},{"description":"Patients with GBM with a translocation involving the ALK gene","id":"OG002","title":"Glioblastoma (GBM)"},{"description":"Patients with any other ALK-positive tumor. Patients in this arm included adenocarcinoma (n= 2), sarcoma (1) and other (2).","id":"OG003","title":"Any Other ALK-positive Tumor"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Baseline up to approximately 16 weeks","title":"Disease Control Rate (DCR) Based on Investigator Assessments for Participants With at Least 16 Weeks of Treatment","type":"PRIMARY","unitOfMeasure":"percentage of participants"}